INTERVIEW: Goldman's dreams of competitive collaboration as IMI 2 considered
This article was originally published in Scrip
Executive Summary
With around €1.2 billion of the Innovative Medicines Initiative's €2 billion budget already spent financing around 40 projects, executive director Michel Goldman's thoughts are turning to the possibility of an IMI 2. He told Scrip in an exclusive interview that he believes the IMI's successes to date are enough to weigh in favor of another IMI scheme, and set out the case for more clinically-oriented elements for the next phase of IMI.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.